8-K: Regen Biopharma Dismisses BF Borgers as Auditor Following SEC Order

Regen Biopharma has dismissed its auditor, BF Borgers CPA PC, effective immediately, due to an SEC order against the firm.

Summary

• Regen Biopharma's Board of Directors approved the dismissal of BF Borgers CPA PC as their independent registered public accounting firm on May 10, 2024.
• The dismissal was a direct result of the Securities and Exchange Commission's order issued on May 3, 2024, against BF Borgers and its sole audit partner, Benjamin F. Borgers.
• The SEC order initiated settled administrative and cease-and-desist proceedings against BF Borgers.
• The audit reports from BF Borgers for the fiscal years ending September 30, 2023 and 2022 did not contain any adverse opinions, disclaimers, or qualifications.
• Regen Biopharma stated that there were no disagreements with BF Borgers on accounting principles, financial disclosures, or auditing procedures during the two most recent fiscal years and the subsequent interim period.
• The SEC has advised that a letter from BF Borgers is not required, as BF Borgers is not permitted to practice before the SEC due to the May 3, 2024 order.

Sentiment

Score: 3

Explanation: The dismissal of an auditor due to an SEC order is a significant negative event, raising concerns about past financial reporting and future compliance. This warrants a low sentiment score.

Positives

• The company's previous audits by BF Borgers did not contain any adverse opinions or qualifications.
• Regen Biopharma reported no disagreements with BF Borgers on accounting or auditing matters.

Negatives

• The company was forced to dismiss its auditor due to an SEC order against the auditing firm.
• The SEC order against BF Borgers indicates potential issues with the firm's practices.

Risks

• The company needs to find a new auditor, which could cause delays in future financial reporting.
• The SEC order against BF Borgers may raise concerns about the reliability of past financial statements audited by the firm.
• The change in auditors could lead to increased scrutiny from investors and regulators.

Industry Context

The dismissal of an auditor due to regulatory action is a significant event that can impact investor confidence and is not a common occurrence. This situation highlights the importance of auditor independence and compliance with regulatory standards.

Comparison to Industry Standards

• The dismissal of an auditor due to an SEC order is unusual and not in line with standard practice.
• Most companies change auditors due to strategic reasons or after a tender process, not due to regulatory issues with the auditor.
• Companies like Enron and Arthur Andersen had similar issues which led to significant negative consequences for the companies and the industry.

Stakeholder Impact

• Shareholders may be concerned about the reliability of past financial statements and the company's future financial reporting.
• The company's reputation may be negatively impacted by the dismissal of its auditor.
• Creditors may be more cautious about lending to the company.

Next Steps

• Regen Biopharma will need to appoint a new independent registered public accounting firm.
• The company will need to ensure a smooth transition to the new auditor.

Key Dates

Keywords

auditor, SEC, BF Borgers, accounting, financial statements, dismissal, audit, Regen Biopharma